Skip to main content
PI

PinkDx, Inc.

PinkDx develops molecular diagnostic tests to improve outcomes for women presenting with vague gynecological cancer symptoms, such as bloating and pelvic pain. By replacing invasive procedures with non-invasive testing, the company aims to reduce the delays in diagnosis and provide timely answers that positively impact women's health.

San Francisco, United StatesFounded 2022182K+ followers
Updated 4 months ago

Funding

$45M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Women presenting with vague gynecological symptoms, such as bloating and pelvic pain, often face diagnostic delays and invasive procedures to rule out gynecological cancers. Current diagnostic methods can be slow, painful, and may not provide timely answers, impacting women's health outcomes.

Solution

PinkDx is developing molecular diagnostic tests designed to improve the diagnostic process for women with vague gynecological symptoms. These non-invasive tests aim to replace traditional invasive procedures, providing faster and more accurate diagnoses. By applying sophisticated scientific approaches, PinkDx seeks to address the challenges in diagnosing gynecological cancers, ultimately leading to earlier detection and more effective treatment. The company leverages a comprehensive collection of patient samples, extracting genomic, medical history, and clinical data. Robust bioinformatic tools and machine learning models are then deployed to develop tests that provide answers based on each woman’s profile.

Target Audience

The primary target audience includes women presenting with vague gynecological symptoms, as well as the healthcare providers, such as gynecologists and oncologists, who diagnose and treat them.

Features

  • Non-invasive molecular diagnostic tests for gynecological cancers
  • Analysis of genomic, medical history, and clinical data from patient samples
  • Bioinformatic tools and machine learning models for test development
  • Aims to replace invasive diagnostic procedures
  • Designed to provide faster and more accurate diagnoses
This profile is AI-generated and may contain inaccuracies.